Difference between revisions of "Team:Georgia State/HP/Silver"

Line 177: Line 177:
 
</div>
 
</div>
 
     <div class="row-fluid">
 
     <div class="row-fluid">
                            <div class="span10 ruler-bottom">
+
                         
 
                                 <div class="block">                   
 
                                 <div class="block">                   
 
<div class="row-fluid">
 
<div class="row-fluid">
Line 201: Line 201:
 
<div class="ruler-bottom"></div>
 
<div class="ruler-bottom"></div>
 
<div class="block">
 
<div class="block">
<h3> Biomedical Threats</h3>
+
<h1 class="media-heading"> Biomedical Threats</h1>
 +
 
 
     <p class="last">Horseshoe crabs do not only face the threat of being used for bait but instead, have a more financially driven predator in the form of the biomedical industry.  If you have ever had a flu shot, known someone with a pacemaker or joint replacement, or given your pet a rabies vaccination, you owe a debt of gratitude to the horseshoe crab. All of these devices are quality checked for safety using a test that comes from the blood of the horseshoe crab. The blood of the crab is very sensitive to endotoxins, the blood from the crab is used commercially to develop the LAL and TAL test. The Limulus amebocyte lysate (LAL)test and was commercialized in the United States in the 1970s and Asia, there is a similar test called TAL which takes its name from an Asian species of crab, Tachypleus tridentatus (Jay Odell, 2005). The market for LAL is approximately $50 million (Focus, 2008). Each year,  half a million living horse crabs are harvested to develop these endotoxin tests- for these kits, companies take 30 percent or more of the horseshoe crabs blood. Experts estimate that 10-15% of 500,000 crabs harvested on the Atlantic coast do not survive the bleeding process (Focus, 2008). Currently, no synthetic substitute has the same accuracy as the LAL test, so crab blood must be used, and thus the threat persists (Focus, 2008).
 
     <p class="last">Horseshoe crabs do not only face the threat of being used for bait but instead, have a more financially driven predator in the form of the biomedical industry.  If you have ever had a flu shot, known someone with a pacemaker or joint replacement, or given your pet a rabies vaccination, you owe a debt of gratitude to the horseshoe crab. All of these devices are quality checked for safety using a test that comes from the blood of the horseshoe crab. The blood of the crab is very sensitive to endotoxins, the blood from the crab is used commercially to develop the LAL and TAL test. The Limulus amebocyte lysate (LAL)test and was commercialized in the United States in the 1970s and Asia, there is a similar test called TAL which takes its name from an Asian species of crab, Tachypleus tridentatus (Jay Odell, 2005). The market for LAL is approximately $50 million (Focus, 2008). Each year,  half a million living horse crabs are harvested to develop these endotoxin tests- for these kits, companies take 30 percent or more of the horseshoe crabs blood. Experts estimate that 10-15% of 500,000 crabs harvested on the Atlantic coast do not survive the bleeding process (Focus, 2008). Currently, no synthetic substitute has the same accuracy as the LAL test, so crab blood must be used, and thus the threat persists (Focus, 2008).
 
</p>
 
</p>

Revision as of 16:58, 1 November 2017